These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29031817)

  • 1. BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.
    Hira D; Terada T
    Biochem Pharmacol; 2018 Jan; 147():201-210. PubMed ID: 29031817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
    Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
    J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
    Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.
    Kim KA; Cha YJ; Lee HM; Joo HJ; Park JY
    Clin Chim Acta; 2015 Jan; 438():7-11. PubMed ID: 25124867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.
    Futatsugi A; Toshimoto K; Yoshikado T; Sugiyama Y; Kato Y
    Drug Metab Dispos; 2018 May; 46(5):749-757. PubMed ID: 29440178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
    Cusatis G; Gregorc V; Li J; Spreafico A; Ingersoll RG; Verweij J; Ludovini V; Villa E; Hidalgo M; Sparreboom A; Baker SD
    J Natl Cancer Inst; 2006 Dec; 98(23):1739-42. PubMed ID: 17148776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
    Murakami M; Ohnuma S; Fukuda M; Chufan EE; Kudoh K; Kanehara K; Sugisawa N; Ishida M; Naitoh T; Shibata H; Iwabuchi Y; Ambudkar SV; Unno M
    Drug Metab Dispos; 2017 Nov; 45(11):1166-1177. PubMed ID: 28904007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
    Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
    Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
    Sparreboom A; Gelderblom H; Marsh S; Ahluwalia R; Obach R; Principe P; Twelves C; Verweij J; McLeod HL
    Clin Pharmacol Ther; 2004 Jul; 76(1):38-44. PubMed ID: 15229462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
    Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
    Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
    Meyer zu Schwabedissen HE; Kroemer HK
    Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
    Kim KA; Joo HJ; Park JY
    J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
    Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
    Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
    Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
    J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.